CytomX Therapeutics Income Statement (2014-2025) | CTMX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	8.20M	8.79M	9.19M	11.13M	9.04M	12.85M	11.15M	20.12M	23.50M	24.72M	26.38M	26.61M	41.46M	25.11M	33.43M	38.09M	50.92M	18.66M	5.96M	0.66M
Operating items
Research & Development (Quarter)	22.37M	26.10M	29.14M	36.58M	30.56M	31.16M	30.37M	19.56M	21.18M	20.67M	16.45M	19.39M	22.05M	25.17M	21.37M	14.79M	18.87M	13.32M	15.30M	21.23M
Selling, General & Administrative (Quarter)	9.23M	9.39M	11.09M	9.46M	10.54M	11.75M	10.49M	10.07M	7.98M	7.40M	6.81M	7.83M	7.75M	8.39M	7.95M	5.62M	9.43M	6.62M	6.43M	7.36M
Operating Expenses (Quarter)	31.60M	35.49M	40.23M	46.03M	41.10M	42.91M	40.86M	29.63M	29.15M	28.07M	23.26M	27.21M	29.81M	33.57M	29.32M	20.41M	28.30M	19.94M	21.73M	28.59M
Operating Income (Quarter)	-23.40M	-26.70M	-31.04M	-34.90M	-32.06M	-30.05M	-29.71M	-9.51M	-5.65M	-3.35M	3.12M	-0.61M	11.66M	-8.45M	4.11M	17.68M	22.62M	-1.29M	-15.77M	-9.17M
EBIT (Quarter)	-23.40M	-26.70M	-31.04M	-34.90M	-32.06M	-30.05M	-29.71M	-9.51M	-5.65M	-3.35M	3.12M	-0.61M	11.66M	-8.45M	4.11M	17.68M	22.62M	-1.29M	-15.77M	-9.17M
Non-operating items
Interest & Investment Income (Quarter)	0.07M	0.04M	0.07M	0.07M	0.07M	0.26M	0.62M	0.73M	2.33M	2.31M	2.70M	2.50M	2.19M	1.97M	1.69M	1.28M	0.95M	1.18M	1.59M	1.48M
Other Non Operating Income (Quarter)	0.01M	-0.08M	-0.01M	0.01M	0.01M	0.30M	0.03M	0.00M	0.01M	-0.05M	-0.01M	0.01M	-0.01M	-0.00M	-0.01M	-0.02M	0.01M	0.02M	0.01M	-0.01M
Non Operating Income (Quarter)	0.01M	-0.08M	-0.01M	0.01M	0.01M	0.30M	0.03M	0.00M	0.01M	-0.05M	-0.01M	0.01M	-0.01M	-0.00M	-0.01M	-0.02M	0.01M	0.02M	0.01M	-0.01M
Net income details
EBT (Quarter)	-23.33M	-26.74M	-30.98M	-34.82M	-31.98M	-29.50M	-29.06M	-8.78M	-3.31M	-1.09M	5.82M	1.91M	13.84M	-6.48M	5.80M	18.94M	23.59M	-0.09M	-14.17M	-26.46M
Tax Provisions (Quarter)											2.82M	1.07M	0.05M	0.05M	0.06M	0.06M	0.06M	0.06M	0.06M	0.05M
Profit After Tax (Quarter)	-23.33M	-26.74M	-30.98M	-34.82M	-31.98M	-29.50M	-29.06M	-8.78M	-3.31M	-1.09M	2.99M	0.84M	13.79M	-6.53M	5.74M	18.88M	23.52M	-0.15M	-14.23M	-26.51M
Income from Continuing Operations (Quarter)	-23.33M	-26.74M	-30.98M	-34.82M	-31.98M	-29.50M	-29.06M	-8.78M	-3.31M	-1.09M	2.99M	0.84M	13.79M	-6.53M	5.74M	18.88M	23.52M	-0.15M	-14.23M	-26.51M
Consolidated Net Income (Quarter)	-23.33M	-26.74M	-30.98M	-34.82M	-31.98M	-29.50M	-29.06M	-8.78M	-3.31M	-1.09M	2.99M	0.84M	13.79M	-6.53M	5.74M	18.88M	23.52M	-0.15M	-14.23M	-26.51M
Income towards Parent Company (Quarter)	-23.33M	-26.74M	-30.98M	-34.82M	-31.98M	-29.50M	-29.06M	-8.78M	-3.31M	-1.09M	2.99M	0.84M	13.79M	-6.53M	5.74M	18.88M	23.52M	-0.15M	-14.23M	-26.51M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-23.33M	-26.74M	-30.98M	-34.82M	-31.98M	-29.50M	-29.06M	-8.78M	-3.31M	-1.09M	2.99M	0.84M	13.79M	-6.53M	5.74M	18.88M	23.52M	-0.15M	-14.23M	-26.51M
Additional items
EPS (Basic) (Quarter)	-0.38	-0.41	-0.48	-0.53	-0.49	-0.45	-0.44	-0.13	-0.05	-0.02	0.04	0.01	0.17	-0.08	0.07	0.23	0.27	0.00	-0.09	-0.22
EPS (Weighted Average and Diluted) (Quarter)	-0.38	-0.41	-0.48	-0.53	-0.49	-0.45	-0.44	-0.13	-0.05	-0.02	0.04	0.01	0.17	-0.08	0.07	0.23	0.27		-0.09	-0.22
Shares Outstanding (Weighted Average) (Quarter)	60.97M	65.06M	65.21M	64.15M	65.39M	65.47M	65.62M	65.74M	66.25M	66.54M	80.73M	14.42M	67.61M	83.46M	85.09M	84.44M	80.20M	129.08M	127.35M	137.94M
Shares Outstanding (Diluted Average) (Quarter)	60.97M	65.06M	65.21M	64.15M	65.39M	65.47M	65.91M	65.74M	66.25M	66.54M		73.81M
EBITDA (Quarter)	-23.32M	-26.68M	-30.95M	-35.12M	-32.66M	-29.74M	-28.70M	-7.97M	-3.29M	-1.08M	2.89M	0.99M	13.69M	-6.53M	5.78M	18.86M	23.50M	-0.12M	-14.16M	-9.17M
Interest Expenses (Quarter)
Tax Rate (Quarter)											48.55%	56.09%	0.35%	-0.79%	1.05%	0.33%	0.26%	-69.23%	-0.41%	-0.20%

Research Tools

CytomX Therapeutics Income Statement (2014-2025) | CTMX

Create an account

Sign In

Reset Password